A Multicenter, Randomized Controlled Study of the Efficacy of Once-Weekly DPP-4 Inhibitor Omarigliptin in Patients with Type 2 Diabetes Undergoing Maintenance Hemodialysis

被引：0
|
作者：
Yoshizawa, Yuta
Hosojima, Michihiro
Kabasawa, Hideyuki
Tanabe, Naohito
Kitamura, Tadahiro
Narita, Ichiei
Saito, Akihiko
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-29-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
29-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] From JANUVIA to MARIZEV (Omarigliptin), a once weekly DPP-4 inhibitor for the treatment of diabetes
    Weber, Ann
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [22] First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
    Kaku, Kohei
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (16) : 2539 - 2547
  • [23] Absorption, Metabolism, and Excretion of [14C] Omarigliptin, a Once-Weekly DPP-4 Inhibitor, in Humans
    Xu, Shiyao
    Kauh, Anya
    Tatosian, Daniel
    Mcintosh, Ian
    Caceres, Maria
    Matthews, Catherine
    Miller, Jutta
    Kumar, Sanjeev
    Wirth, Mark
    DIABETES, 2014, 63 : A281 - A281
  • [24] Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans
    Xu, Shiyao
    Tatosian, Dan
    Mcintosh, Ian
    Caceres, Maria
    Matthews, Catherine
    Samuel, Koppara
    Selverian, Diana
    Kumar, Sanjeev
    Kauh, Eunkyung
    XENOBIOTICA, 2018, 48 (06) : 584 - 591
  • [25] Once-weekly DPP-4 inhibitors: The clinical efficacy and treatment satisfaction in 51 Japanese patients with type 2 diabetes mellitus
    Tosaki, Takahiro
    Kamiya, Hideki
    Himeno, Tatsuhito
    Kato, Yoshiro
    Kondo, Masaki
    Inagaki, Akemi
    Yamamoto, Yuka
    Tsubonaka, Kaori
    Oshiro, Chie
    Nakaya, Yuki
    Hayasaki, Tomoyo
    Nakamura, Jiro
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S127 - S127
  • [26] A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
    Gantz, Ira
    Okamoto, Taro
    Ito, Yuka
    Okuyama, Kotoba
    O'Neill, Edward A.
    Kaufman, KeithD.
    Engel, Samuel S.
    Lai, Eseng
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1602 - 1609
  • [27] A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Shankar, R. Ravi
    Inzucchi, Silvio E.
    Scarabello, Victoria
    Gantz, Ira
    Kaufman, Keith D.
    Lai, Eseng
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Engel, Samuel S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1853 - 1860
  • [28] Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes
    Tosaki, Takahiro
    Kamiya, Hideki
    Yamamoto, Yuka
    Himeno, Tatsuhito
    Kato, Yoshiro
    Kondo, Masaki
    Yamada, Yuichiro
    Inagaki, Akemi
    Tsubonaka, Kaori
    Oshiro, Chie
    Katayama, Takami
    Hayasaki, Tomoyo
    Nakaya, Yuki
    Fujiyoshi, Haruna
    Nakamura, Jiro
    INTERNAL MEDICINE, 2017, 56 (19) : 2563 - 2569
  • [29] Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)
    Ishii, Hitoshi
    Kamei, Nozomu
    Shimono, Dai
    Niiya, Tetsuji
    Tosaki, Takahiro
    Kitazawa, Toru
    Suzuki, Daisuke
    Wakasa, Yutaka
    Seino, Hiroaki
    Oishi, Mariko
    Ohashi, Hiroshi
    Higami, Kenshi
    Akai, Hiroaki
    DIABETES THERAPY, 2023, 14 (10) : 1639 - 1658
  • [30] Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)
    Hitoshi Ishii
    Nozomu Kamei
    Dai Shimono
    Tetsuji Niiya
    Takahiro Tosaki
    Toru Kitazawa
    Daisuke Suzuki
    Yutaka Wakasa
    Hiroaki Seino
    Mariko Oishi
    Hiroshi Ohashi
    Kenshi Higami
    Hiroaki Akai
    Diabetes Therapy, 2023, 14 : 1639 - 1658
12345